JP6833851B2 - 組み換えヒトｃｄ３８細胞外ドメインを含む組成物および／または方法および／またはキット - Google Patents
組み換えヒトｃｄ３８細胞外ドメインを含む組成物および／または方法および／またはキット Download PDFInfo
- Publication number
- JP6833851B2 JP6833851B2 JP2018530834A JP2018530834A JP6833851B2 JP 6833851 B2 JP6833851 B2 JP 6833851B2 JP 2018530834 A JP2018530834 A JP 2018530834A JP 2018530834 A JP2018530834 A JP 2018530834A JP 6833851 B2 JP6833851 B2 JP 6833851B2
- Authority
- JP
- Japan
- Prior art keywords
- tag
- antibody
- cd38ecd
- seq
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 68
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 title claims description 67
- 239000000203 mixture Substances 0.000 title claims description 60
- 102000052645 human CD38 Human genes 0.000 title claims description 14
- 210000002381 plasma Anatomy 0.000 claims description 86
- 238000006384 oligomerization reaction Methods 0.000 claims description 70
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 53
- 210000004369 blood Anatomy 0.000 claims description 41
- 239000008280 blood Substances 0.000 claims description 41
- 108060003951 Immunoglobulin Proteins 0.000 claims description 37
- 102000018358 immunoglobulin Human genes 0.000 claims description 37
- 238000012360 testing method Methods 0.000 claims description 34
- 230000027455 binding Effects 0.000 claims description 28
- 210000002966 serum Anatomy 0.000 claims description 28
- 241000282414 Homo sapiens Species 0.000 claims description 22
- 210000003743 erythrocyte Anatomy 0.000 claims description 22
- 230000003472 neutralizing effect Effects 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 13
- 230000000903 blocking effect Effects 0.000 claims description 11
- 238000003556 assay Methods 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 10
- 229950007752 isatuximab Drugs 0.000 claims description 10
- 101710201279 Biotin carboxyl carrier protein Proteins 0.000 claims description 6
- 238000002616 plasmapheresis Methods 0.000 claims description 6
- 102000005720 Glutathione transferase Human genes 0.000 claims description 5
- 108010070675 Glutathione transferase Proteins 0.000 claims description 5
- 102000002669 Small Ubiquitin-Related Modifier Proteins Human genes 0.000 claims description 5
- 108010043401 Small Ubiquitin-Related Modifier Proteins Proteins 0.000 claims description 5
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 4
- 230000009465 prokaryotic expression Effects 0.000 claims description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- 108010020346 Polyglutamic Acid Proteins 0.000 claims description 3
- 238000009175 antibody therapy Methods 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 108091006047 fluorescent proteins Proteins 0.000 claims description 3
- 102000034287 fluorescent proteins Human genes 0.000 claims description 3
- 238000001631 haemodialysis Methods 0.000 claims description 3
- 125000001475 halogen functional group Chemical group 0.000 claims description 3
- 230000000322 hemodialysis Effects 0.000 claims description 3
- 238000002615 hemofiltration Methods 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 229920002643 polyglutamic acid Polymers 0.000 claims description 3
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 claims description 2
- 238000012286 ELISA Assay Methods 0.000 claims description 2
- 108010024636 Glutathione Proteins 0.000 claims description 2
- 238000003149 assay kit Methods 0.000 claims description 2
- 229960003180 glutathione Drugs 0.000 claims description 2
- 108010018381 streptavidin-binding peptide Proteins 0.000 claims description 2
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 claims 1
- 239000012634 fragment Substances 0.000 description 89
- 210000004027 cell Anatomy 0.000 description 56
- 239000000523 sample Substances 0.000 description 46
- 239000000499 gel Substances 0.000 description 40
- 229960002204 daratumumab Drugs 0.000 description 38
- 102000004169 proteins and genes Human genes 0.000 description 38
- 108090000623 proteins and genes Proteins 0.000 description 38
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 36
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 36
- 235000018102 proteins Nutrition 0.000 description 36
- 102000037865 fusion proteins Human genes 0.000 description 35
- 108020001507 fusion proteins Proteins 0.000 description 35
- 229920002704 polyhistidine Polymers 0.000 description 31
- 230000001629 suppression Effects 0.000 description 29
- 238000012216 screening Methods 0.000 description 25
- 108090000765 processed proteins & peptides Proteins 0.000 description 24
- 230000014509 gene expression Effects 0.000 description 22
- 102000004196 processed proteins & peptides Human genes 0.000 description 22
- 229920001184 polypeptide Polymers 0.000 description 21
- 238000011534 incubation Methods 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 17
- 229940094732 darzalex Drugs 0.000 description 15
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 15
- 108020004707 nucleic acids Proteins 0.000 description 15
- 102000039446 nucleic acids Human genes 0.000 description 15
- 150000007523 nucleic acids Chemical class 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 14
- 125000003275 alpha amino acid group Chemical group 0.000 description 12
- 238000003776 cleavage reaction Methods 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 230000003606 oligomerizing effect Effects 0.000 description 12
- 230000007017 scission Effects 0.000 description 12
- 238000001514 detection method Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 230000001788 irregular Effects 0.000 description 11
- 239000013610 patient sample Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 102000035195 Peptidases Human genes 0.000 description 8
- 108091005804 Peptidases Proteins 0.000 description 8
- 239000000539 dimer Substances 0.000 description 8
- 230000000670 limiting effect Effects 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 238000004448 titration Methods 0.000 description 8
- 206010035226 Plasma cell myeloma Diseases 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 238000001597 immobilized metal affinity chromatography Methods 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 239000004365 Protease Substances 0.000 description 6
- 108010076818 TEV protease Proteins 0.000 description 6
- 241000723792 Tobacco etch virus Species 0.000 description 6
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 235000019419 proteases Nutrition 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- -1 BNPS-scatol Proteins 0.000 description 5
- 208000034578 Multiple myelomas Diseases 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 235000014304 histidine Nutrition 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 239000013638 trimer Substances 0.000 description 5
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- 230000000735 allogeneic effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 241000272517 Anseriformes Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000000710 homodimer Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- NQUNIMFHIWQQGJ-UHFFFAOYSA-N 2-nitro-5-thiocyanatobenzoic acid Chemical compound OC(=O)C1=CC(SC#N)=CC=C1[N+]([O-])=O NQUNIMFHIWQQGJ-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- NHZLNPMOSADWGC-UHFFFAOYSA-N 4-amino-N-(2-quinoxalinyl)benzenesulfonamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CN=C(C=CC=C2)C2=N1 NHZLNPMOSADWGC-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 229940124295 CD38 monoclonal antibody Drugs 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 102000005853 Clathrin Human genes 0.000 description 2
- 108010019874 Clathrin Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000005593 Endopeptidases Human genes 0.000 description 2
- 108010059378 Endopeptidases Proteins 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 108091006020 Fc-tagged proteins Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000009582 blood typing Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 229930193282 clathrin Natural products 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000034628 Celiac artery compression syndrome Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 108010028275 Leukocyte Elastase Proteins 0.000 description 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100033174 Neutrophil elastase Human genes 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 102000015795 Platelet Membrane Glycoproteins Human genes 0.000 description 1
- 108010010336 Platelet Membrane Glycoproteins Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000056251 Prolyl Oligopeptidases Human genes 0.000 description 1
- 108700015930 Prolyl Oligopeptidases Proteins 0.000 description 1
- 229940022005 RNA vaccine Drugs 0.000 description 1
- 206010049190 Red blood cell agglutination Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000003441 Transfusion reaction Diseases 0.000 description 1
- 108010070926 Tripeptide aminopeptidase Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229940126590 dalatumumab Drugs 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 108700021021 mRNA Vaccine Proteins 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002625 monoclonal antibody therapy Methods 0.000 description 1
- 238000000569 multi-angle light scattering Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- IFPHDUVGLXEIOQ-UHFFFAOYSA-N ortho-iodosylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I=O IFPHDUVGLXEIOQ-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000012910 preclinical development Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762543788P | 2017-08-10 | 2017-08-10 | |
| US62/543,788 | 2017-08-10 | ||
| PCT/IB2018/053939 WO2019030581A1 (en) | 2017-08-10 | 2018-06-01 | COMPOSITIONS, METHODS AND / OR KITS COMPRISING AN EXTRACELLULAR DOMAIN OF RECOMBINANT HUMAN CD38 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021015874A Division JP7289328B2 (ja) | 2017-08-10 | 2021-02-03 | 組み換えヒトｃｄ３８細胞外ドメインを含む組成物および／または方法および／またはキット |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019527533A JP2019527533A (ja) | 2019-10-03 |
| JP6833851B2 true JP6833851B2 (ja) | 2021-02-24 |
Family
ID=62846219
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018530834A Active JP6833851B2 (ja) | 2017-08-10 | 2018-06-01 | 組み換えヒトｃｄ３８細胞外ドメインを含む組成物および／または方法および／またはキット |
| JP2021015874A Active JP7289328B2 (ja) | 2017-08-10 | 2021-02-03 | 組み換えヒトｃｄ３８細胞外ドメインを含む組成物および／または方法および／またはキット |
| JP2023012758A Pending JP2023041802A (ja) | 2017-08-10 | 2023-01-31 | 組み換えヒトｃｄ３８細胞外ドメインを含む組成物および／または方法および／またはキット |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021015874A Active JP7289328B2 (ja) | 2017-08-10 | 2021-02-03 | 組み換えヒトｃｄ３８細胞外ドメインを含む組成物および／または方法および／またはキット |
| JP2023012758A Pending JP2023041802A (ja) | 2017-08-10 | 2023-01-31 | 組み換えヒトｃｄ３８細胞外ドメインを含む組成物および／または方法および／またはキット |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11708418B2 (enExample) |
| EP (3) | EP3587445B1 (enExample) |
| JP (3) | JP6833851B2 (enExample) |
| KR (2) | KR20240015159A (enExample) |
| CN (2) | CN117820498A (enExample) |
| AR (1) | AR112357A1 (enExample) |
| AU (2) | AU2018313028B2 (enExample) |
| BR (1) | BR112020002636A2 (enExample) |
| CA (1) | CA3070789A1 (enExample) |
| EA (1) | EA202090265A1 (enExample) |
| ES (2) | ES2973864T3 (enExample) |
| HU (1) | HUE065510T2 (enExample) |
| MX (3) | MX2020001489A (enExample) |
| PL (1) | PL3587445T3 (enExample) |
| PT (1) | PT3587445T (enExample) |
| TW (1) | TW201910349A (enExample) |
| UY (1) | UY37757A (enExample) |
| WO (1) | WO2019030581A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR112357A1 (es) * | 2017-08-10 | 2019-10-23 | Grifols Diagnostic Solutions Inc | Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano |
| TW202000692A (zh) * | 2018-02-20 | 2020-01-01 | 美商格里佛診斷方法股份有限公司 | 包含GpIbα的多肽和組合物、編碼該多肽的核酸及包含該多肽或該核酸的細胞 |
| CN112048019B (zh) * | 2019-06-06 | 2023-05-09 | 鲁南制药集团股份有限公司 | 抗人cd47单克隆抗体 |
| AU2021338773A1 (en) * | 2020-09-10 | 2023-05-25 | Casi Pharmaceuticals, Inc. | Methods of blood screening |
| CN112285361B (zh) * | 2020-09-27 | 2023-12-05 | 中国人民解放军空军军医大学 | 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂 |
| CN114917413B (zh) * | 2022-06-14 | 2023-04-28 | 健诺维(成都)生物科技有限公司 | 一种负载重组多肽的羊膜及其制备方法 |
| WO2024172419A1 (ko) * | 2023-02-16 | 2024-08-22 | 주식회사 디엔티 | Cd38 또는 이의 단편을 포함하는 자가면역질환 치료용 조성물 |
| CN117723749B (zh) * | 2024-02-07 | 2024-06-04 | 南昌大学 | 基于分子粘合剂的动态光散射免疫传感检测方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994511A (en) * | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
| US6506551B1 (en) * | 1999-10-08 | 2003-01-14 | North Shore - Long Island Jewish Research Institute | CD38 as a prognostic indicator in B cell chronic lymphocytic leukemia |
| AU2001273121A1 (en) * | 2000-06-30 | 2002-01-14 | Pharmacia And Upjohn Company | Recombinant staphylococcus aureus peptide deformylase |
| EP1697520A2 (en) * | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| SI2511297T1 (sl) * | 2004-02-06 | 2015-07-31 | Morphosys Ag | Proti -CD38 humana protitelesa in njihova uporaba |
| EP3753576A1 (en) * | 2006-09-26 | 2020-12-23 | Genmab A/S | Combination treatment of cd38-expressing tumors |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| CN103897063B (zh) * | 2007-06-01 | 2017-04-12 | 马里兰大学巴尔的摩分校 | 免疫球蛋白恒定区Fc受体结合剂 |
| EP2388270A3 (en) * | 2007-10-11 | 2012-04-25 | The Hospital For Sick Children | Modulation of SIRPa - CD47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor |
| WO2010037837A2 (en) * | 2008-10-01 | 2010-04-08 | Micromet Ag | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
| SG194399A1 (en) * | 2008-10-01 | 2013-11-29 | Amgen Res Munich Gmbh | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody |
| WO2010083253A2 (en) * | 2009-01-14 | 2010-07-22 | Viral Logic Systems Technology Corp. | Cd47 related compositions and methods for treating immunological diseases and disorders |
| PL3053932T3 (pl) * | 2010-02-19 | 2021-03-08 | Xencor, Inc. | Nowe immunoadhezyny CTLA4-IG |
| US20130029358A1 (en) * | 2010-04-01 | 2013-01-31 | Ludwig Institute For Cancer Research Ltd. | Immunodominant mhc dr52b restricted ny-eso-1 epitopes, mhc class ii monomers and multimers, and uses thereof |
| SG188328A1 (en) * | 2010-09-03 | 2013-04-30 | Stem Centrx Inc | Novel modulators and methods of use |
| EP2530089A1 (en) * | 2011-06-03 | 2012-12-05 | Bayer Pharma Aktiengesellschaft | Neutralising prolactin receptor antibody Mat3 and its therapeutical use |
| EP2812443B1 (en) * | 2012-02-06 | 2019-05-29 | Inhibrx, Inc. | Cd47 antibodies and methods of use thereof |
| ES2857900T3 (es) * | 2012-04-27 | 2021-09-29 | Novo Nordisk As | Proteínas de unión a antígeno de ligando CD30 humano |
| SG11201408646VA (en) * | 2012-07-06 | 2015-01-29 | Genmab Bv | Dimeric protein with triple mutations |
| US9447193B2 (en) * | 2013-03-24 | 2016-09-20 | Development Center For Biotechnology | Methods for suppressing cancer by inhibition of TMCC3 |
| US9599606B2 (en) * | 2014-06-10 | 2017-03-21 | The Board Of Regents Of The University Of Texas System | ADP-ribose detection reagents |
| KR102252119B1 (ko) * | 2014-06-18 | 2021-05-17 | 앨버트 아인슈타인 컬리지 오브 메디신 | Syntac 폴리펩티드 및 이의 용도 |
| MA40894A (fr) * | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| WO2016081423A1 (en) * | 2014-11-18 | 2016-05-26 | Janssen Pharmaceutica Nv | Cd47 antibodies, methods, and uses |
| EP3263599A4 (en) * | 2015-02-16 | 2018-12-19 | Pharma Foods International Co., Ltd. | Anti-cancer agent and antimetastatic agent using fstl1, and concomitant drug for same |
| US9580477B2 (en) * | 2015-03-16 | 2017-02-28 | The Catholic University Of America | Approach to produce HIV-1 GP140 envelope protein trimers |
| SI3274370T1 (sl) * | 2015-03-23 | 2020-02-28 | Bayer Pharma Aktiengesellschaft | Protitelesa proti CEACAM6 in njihova uporaba |
| CA2989993A1 (en) * | 2015-09-08 | 2017-03-16 | Eisai R&D Management Co., Ltd. | Anti-epha4 antibody |
| JP2019503167A (ja) * | 2015-11-10 | 2019-02-07 | ユニバーシティ・メディカル・センター・ハンブルク−エッペンドルフＵｎｉｖｅｒｓｉｔｙ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ Ｈａｍｂｕｒｇ − Ｅｐｐｅｎｄｏｒｆ | Ｃｄ３８に対する抗原結合性ポリペプチド |
| AR112357A1 (es) * | 2017-08-10 | 2019-10-23 | Grifols Diagnostic Solutions Inc | Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano |
-
2018
- 2018-06-01 AR ARP180101480 patent/AR112357A1/es unknown
- 2018-06-01 EP EP19184018.0A patent/EP3587445B1/en active Active
- 2018-06-01 ES ES19184018T patent/ES2973864T3/es active Active
- 2018-06-01 PT PT191840180T patent/PT3587445T/pt unknown
- 2018-06-01 US US16/079,068 patent/US11708418B2/en active Active
- 2018-06-01 KR KR1020247002508A patent/KR20240015159A/ko active Pending
- 2018-06-01 EA EA202090265A patent/EA202090265A1/ru unknown
- 2018-06-01 ES ES18738376T patent/ES2911243T3/es active Active
- 2018-06-01 HU HUE19184018A patent/HUE065510T2/hu unknown
- 2018-06-01 MX MX2020001489A patent/MX2020001489A/es unknown
- 2018-06-01 KR KR1020187017279A patent/KR102631281B1/ko active Active
- 2018-06-01 JP JP2018530834A patent/JP6833851B2/ja active Active
- 2018-06-01 WO PCT/IB2018/053939 patent/WO2019030581A1/en not_active Ceased
- 2018-06-01 BR BR112020002636-0A patent/BR112020002636A2/pt unknown
- 2018-06-01 PL PL19184018.0T patent/PL3587445T3/pl unknown
- 2018-06-01 CA CA3070789A patent/CA3070789A1/en active Pending
- 2018-06-01 EP EP23205907.1A patent/EP4296680A3/en not_active Withdrawn
- 2018-06-01 UY UY0001037757A patent/UY37757A/es not_active Application Discontinuation
- 2018-06-01 CN CN202410194213.6A patent/CN117820498A/zh active Pending
- 2018-06-01 EP EP18738376.5A patent/EP3464343B1/en active Active
- 2018-06-01 TW TW107119019A patent/TW201910349A/zh unknown
- 2018-06-01 AU AU2018313028A patent/AU2018313028B2/en active Active
- 2018-06-01 CN CN201880000662.5A patent/CN109790210B/zh active Active
-
2020
- 2020-02-06 MX MX2024005669A patent/MX2024005669A/es unknown
- 2020-02-06 MX MX2024008109A patent/MX2024008109A/es unknown
-
2021
- 2021-02-03 JP JP2021015874A patent/JP7289328B2/ja active Active
-
2023
- 2023-01-31 JP JP2023012758A patent/JP2023041802A/ja active Pending
- 2023-05-19 US US18/320,912 patent/US20240228651A9/en active Pending
- 2023-06-28 AU AU2023204121A patent/AU2023204121A1/en active Pending
- 2023-11-20 US US18/514,624 patent/US20240092929A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6833851B2 (ja) | 組み換えヒトｃｄ３８細胞外ドメインを含む組成物および／または方法および／またはキット | |
| Schellekens et al. | Immunogenicity of therapeutic proteins | |
| Kruljec et al. | Alternative affinity ligands for immunoglobulins | |
| Ko et al. | An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies | |
| Seijsing et al. | In vivo depletion of serum IgG by an affibody molecule binding the neonatal Fc receptor | |
| US8618247B2 (en) | Peptide, use of the peptide, method for the production of the peptide, solid support having the peptide immobilized thereon, and method for production of the solid support | |
| Rispens et al. | Fc–Fc interactions of human IgG4 require dissociation of heavy chains and are formed predominantly by the intra-chain hinge isomer | |
| WO2021160805A1 (en) | Immunoglobulin detection and associated therapies | |
| Mikula et al. | The translocation domain in trimeric autotransporter adhesins is necessary and sufficient for trimerization and autotransportation | |
| Kaul et al. | Dissection of C1q capability of interacting with IgG: time-dependent formation of a tight and only partly reversible association | |
| CN114702580B (zh) | 特异性结合人血清白蛋白单克隆抗体及其应用 | |
| Song et al. | Protective effect of scFv‐DAF fusion protein on the complement attack to acetylcholine receptor: A possible option for treatment of myasthenia gravis | |
| BR122024021835A2 (pt) | Composição para ligação a um anticorpo anti-cd47, kit para investigação de biomonitoramento e ensaios de diagnóstico, métodos para: neutralização ou bloqueio da ligação de um anticorpo anti-cd47, seleção de uma unidade adequada de hemácias e remoção de anti-cd47 no plasma, soro e/ou sangue humano, e proteína de fusão. | |
| Yu et al. | Method for studying immunoglobulin G binding on hydrophobic surfaces | |
| BR122024021803A2 (pt) | Marcador de oligomerização para uma proteína de fusão recombinante, e proteína de fusão | |
| EP4308602A1 (en) | Peptides and use thereof for diagnosing and treating antiphospholipid syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180724 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190910 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191108 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20191108 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200512 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200811 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210105 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210203 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6833851 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |